Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune Surveillance
Authors:
- Thomas FabreTFThomas Fabre
- Eleanore HendricksonEHEleanore Hendrickson
- Katherine McGourtyKMKatherine McGourty
- Paola M. MarcovecchioPMPaola M. Marcovecchio
- James McMahonJMJames McMahon
- Sara PattiSPSara Patti
- KaiLi CageKCKaiLi Cage
- Stephen SearlesSSStephen Searles
- Christella WidjajaCWChristella Widjaja
- Christopher StairikerCSChristopher Stairiker
- Kathryn BoundKBKathryn Bound
- Roxanne MartinoRMRoxanne Martino
Preprint
Abstract
Background: Checkpoint inhibitors improve survival in patients with several types of tumors. However, resistance to checkpoint inhibitors creates an opportunity for patients to benefit from novel immunotherapies. The type 2 cytokines IL-4, IL-13 and TSLP have been implicated in suppressing anti-tumor immune responses through T and myeloid cells. Our current study tested whether combined therapeutic blockade of IL-4, IL-13 and TSLP improved anti-tumor immunity alone and in combination with PD1 antagonism. Methods: We used in vitro experiments with primary cells to identify cell types likely to participate in controlling tumors upon IL-4, IL-13, TSLP and PD1 blockade. Therapeutic blockade in the subcutaneous CT26 model tested in vivo tumor growth inhibition and associated immunological changes. Bioinformatic analysis of human tumor bulk RNA sequencing data probed for survival associations with IL-4/IL-13 and TSLP transcriptional responses. Results: In vitro , IL-4 suppressed T cell-mediated tumor growth inhibition and reduced monocyte-derived dendritic cell expression of proteins associated with anti-tumor immunity. In vivo , blocking IL-4, IL-13, TSLP and PD1 improved tumor growth inhibition by creating “hotter” tumors. This was associated with repolarization of CD4 and CD8 T cells and shifts in monocyte, conventional type 1 and type 2 (or monocyte-derived) dendritic cell programs. Transcriptional responses to IL-4/IL-13 and TSLP were associated with poor survival outcomes across patients with several types of cancers. Conclusion: Therapeutic blockade of IL-4, IL-13 and TSLP may drive immunological tumor growth inhibition in subsets of cancer patients alone and in combination with checkpoint inhibitors. Improved tumor growth inhibition was likely driven through augmented cytotoxic T cell priming in secondary lymphoid organs and improved reactivation by repolarized monocytes and dendritic cells in tumors.Keywords
This publication has 104 references indexed in Scilit:
- Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loopCancer Cell, 2022
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesCancer Cell, 2020
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCancer Cell, 2020
- Acquired Resistance to Immune Checkpoint InhibitorsCancer Cell, 2020
- Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic ReviewDrug Safety, 2018
- IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse modelCancer Immunology, Immunotherapy, 2017
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityCancer Cell, 2014
- Elevated Epidermal Thymic Stromal Lymphopoietin Levels Establish an Antitumor Environment in the SkinCancer Cell, 2012
- Loss of Cutaneous TSLP-Dependent Immune Responses Skews the Balance of Inflammation from Tumor Protective to Tumor PromotingCancer Cell, 2012
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of MacrophagesCancer Cell, 2009